{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:14:41Z","timestamp":1794492881974,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["12\/35\/38"],"award-info":[{"award-number":["12\/35\/38"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011377","name":"Glaucoma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007817","name":"Alcon Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ophtha.2025.09.023","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:09:51Z","timestamp":1759360191000},"page":"169-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2804","authenticated-orcid":false,"given":"Giovanni","family":"Montesano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Crabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Garway-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Konstantakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10180","key":"10.1016\/j.ophtha.2025.09.023_bib1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2025.09.023_bib3","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ophtha.2020.03.029","article-title":"Visual field outcomes from the multicenter, randomized controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)","volume":"127","author":"Wright","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2025.09.023_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1167\/iovs.66.1.32","article-title":"Relationship between intraocular pressure and the true rate of functional and structural progression in the United Kingdom Glaucoma Treatment Study","volume":"66","author":"Montesano","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ophtha.2025.09.023_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.13.4.15","article-title":"Estimating the distribution of true rates of visual field progression in glaucoma","volume":"13","author":"Montesano","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.09.023_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0008-4182(03)80060-1","article-title":"Canadian perspectives in glaucoma management: setting target intraocular pressure range","volume":"38","author":"Damji","year":"2003","journal-title":"Can J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ophtha.2025.09.023_bib7","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2017.04.035","article-title":"Evidence-based criteria for assessment of visual field reliability","volume":"124","author":"Yohannan","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2025.09.023_bib8","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1167\/iovs.14-16329","article-title":"Estimating the true distribution of visual field progression rates in glaucoma","volume":"56","author":"Anderson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/tvst.11.2.16","article-title":"Rates of glaucoma progression derived from linear mixed models using varied random effect distributions","volume":"11","author":"Swaminathan","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ophtha.2025.09.023_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajo.2024.08.023","article-title":"Does the visual field improve after initiation of intraocular pressure lowering in the United Kingdom Glaucoma Treatment Study?","volume":"269","author":"Reddingius","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.09.023_bib11","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3389\/fpsyg.2019.02767","article-title":"Indices of effect existence and significance in the Bayesian framework","volume":"10","author":"Makowski","year":"2019","journal-title":"Front Psychol"},{"key":"10.1016\/j.ophtha.2025.09.023_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ajo.2023.02.008","article-title":"Five-year visual field outcomes of the HORIZON Trial","volume":"251","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.09.023_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajo.2022.09.011","article-title":"Two-year visual field outcomes of the Treatment of Advanced Glaucoma Study (TAGS)","volume":"246","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2025.09.023_bib14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ophtha.2024.02.008","article-title":"Relationship between intraocular pressure fluctuation and visual field progression rates in the United Kingdom Glaucoma Treatment Study","volume":"131","author":"Rabiolo","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","article-title":"Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial","volume":"114","author":"Bengtsson","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2025.09.023_bib16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.09.023_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006047","article-title":"The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: a randomized clinical trial","volume":"96","author":"Kiddee","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ophtha.2025.09.023_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcjo.2024.11.010","article-title":"Twenty four-hour intraocular pressure fluctuation in treated glaucoma patients: a pilot study","volume":"60","author":"Ruparelia","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.09.023_bib19","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1111\/aos.12689","article-title":"Effect of topical prostaglandin analogues on corneal hysteresis","volume":"93","author":"Bolivar","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/02713683.2022.2099903","article-title":"A review of corneal biomechanics and scleral stiffness in topical prostaglandin analog therapy for glaucoma","volume":"48","author":"Shen","year":"2023","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.ophtha.2025.09.023_bib21","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1111\/aos.14170","article-title":"Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers","volume":"97","author":"Sanchez-Barahona","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.09.023_bib22","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajo.2007.09.038","article-title":"A visual field index for calculation of glaucoma rate of progression","volume":"145","author":"Bengtsson","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2025.09.023_bib24","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1167\/iovs.10-6905","article-title":"Properties of the statpac visual field index","volume":"52","author":"Artes","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ophtha.2025.09.023_bib25","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1167\/iovs.05-0827","article-title":"Visual field progression in glaucoma: total versus pattern deviation analyses","volume":"46","author":"Artes","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib26","first-page":"417","article-title":"Response variability in the visual field: comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes","volume":"41","author":"Henson","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ophtha.2025.09.023_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.10.12.4","article-title":"Hierarchical censored Bayesian analysis of visual field progression","volume":"10","author":"Montesano","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.09.023_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22040","article-title":"Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study","volume":"22","author":"Garway-Heath","year":"2018","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ophtha.2025.09.023_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2021.04.008","article-title":"Improving the power of glaucoma neuroprotection trials using existing visual field data","volume":"229","author":"Montesano","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ogla.2019.01.009","article-title":"Glaucoma neuroprotection trials are practical using visual field outcomes","volume":"2","author":"Quigley","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"issue":"2","key":"10.1016\/j.ophtha.2025.09.023_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ogla.2019.01.004","article-title":"Improving the feasibility of glaucoma clinical trials using trend-based visual field progression endpoints","volume":"2","author":"Wu","year":"2019","journal-title":"Ophthalmol Glaucoma"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:54:00Z","timestamp":1777492440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025006104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0161642025006104"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.023","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}